







RESEARCH CONFERENCES

ESF-UB Conference in Biomedicine

Pharmacogenetics and Pharmacogenomics

Hotel Eden Roc, Sant Feliu de Guixols • Spain 15-20 June 2007

Chair: Philippe H. Beaune, INSERM U775, FR

Co-Chair: Michel Eichelbaum, Dr. Margarete Fischer-Bosch-

Institut für Klinische Pharmakologie, DE

Vice-Chair: Marçal Pastor Anglada, University of

Barcelona, ES

www.esf.org/conferences/07232

With support from






Sanofi-Aventis

Servier

Roche



www.esf.org

Final Programme

Friday 15 June

Late afternoon / early evening

Registration at the ESF-RC desk

19.00 Welcome Drink

20.00 Dinner

Saturday 16 June

Conference Opening - Plenary Lecture 1

Chair: Philippe Beaune, INSERM U775, FR

08.30-09.30 Michel Eichelbaum

Dr. Margarete Fischer-Bosch-Institut für Klinische Pharmakologie, Stuttgart, DE

Pharmacogenetics: where do we stand in 2007?

Session 1: Gene Variability & New Technology in Genotyping

Chair: Michel Eichelbaum, Dr. Margarete Fischer-Bosch-Institut für Klinische Pharmakologie, DE

09.30-10.00 Roderic Guigó

Center for Genomic Regulation, Barcelona, ES The Complexity of Human Genes

10.00-10.30 Ann-Christine Syvänen

Uppsala University, SE

Alleic imbalance in gene expression as a guide to cis-acting regulatory

polymorphisms

10.30-11.00 Coffee Break

11.00-11.30 Stephan Buch

University of Kiel, DE

Genome-wide association studies

Session 2: Data Analysis & Management, Biostatistics & Bioinformatics

Chair: Roderic Guigó, Center for Genomic Regulation, Barcelona, ES

11.30-12.00 Tom Freeman

University of Edinburgh, UK

Integration and Analysis of Omics Data in 3-Dimensional Network Graphs

12.00-12.30 Alison Motsinger

North Carolina State University, Durham, US

The importance of Epistasis

12.30-13.00 Jaume Bertranpetit

Universitat Pompeu Fabra, Barcelona, ES

Human genome diversity and implications for farmacogenomics

13.00 Lunch

14.30-16.30 Poster Session 1 16.30-17.00 Coffee Break

Session 2: Data Analysis & Management, Biostatistics & Bioinformatics - continued

Chair: Jaume Bertranpetit, Universitat Pompeu Fabra, Barcelona, ES

17.00-17.15 Paul Cizdziel (short talk)

RIKEN Yokohama Institute, JP

Mutation detection and SNP genotyping in 30 minutes; A novel isothermal

amplification technology

17.15-17.30 Pinchas Akiva (short talk)

Compugen, Tel Aviv, IL

GeneVa, a novel platform for computational discovery and high throughput

screening of genomic INDELs, discovers a potential diabetes type 2

susceptibility variation

17.30-17.45 Oksana Makeeva (short talk)

Tomsk Research Institute of Medical Genetics of RAMSc, RU

Global pharmacogenetics: clinically relevant variants of metabolizing enzymes capture the genetic substructure of Eurasian populations

17.45-18.00 James Scott (short talk)

Imperial College, London, UK

Whole genome association identifies novel and known DNA variants associated with component phenotypes of Metabolic Syndrome

Plenary Lecture 2

Chair: Laurent Becquemont, Unite de Recherche Clinique Paris-Sud Hôpital Bicêtre, FR

18.00-19.00 Kevin Cheeseman

AstraZeneca, Loughborough, UK

Pharmacogenetics in the Pharmaceutical Industry

19.00 Dinner

Round Table 1: Implications of PG for Pharmaceutical Industry

Chair: Kevin Cheeseman, AstraZeneca, Loughborough, UK

20.45-21.05 Klaus Lindpainter

F. Hoffmann-La Roche Ltd, Basel, CH

Tba

21.05-21.25 Chris Chamberlain

Roche Products, Welwyn Garden City, UK

Pharmacogenomics and the post marketing lifecycle

21.25-22.00 Plenary Discussion

Sunday 17 June

Session 3: Scientific Bases of PG – 1. Metabolism

Chair: Philippe Beaune, INSERM U775, FR

09.00-09.45 Magnus Ingelman-Sundberg

Karolinska Institute, Stockholm, SE

Genetic variabilty of cytochrome P450 enzymes and receptors

09.45-10.15 Michael Coughtrie

University of Dundee, UK

Pharmacogenetics of UDP-Glucuronosyltransferases

10.15-10.30 Maria Gabriella Scordo (short talk)

University of Uppsala, SE

Apo-E genotype and donepezil therapy clinical outcome in patients with

Alzheimer's Disease

10.30-11.00 Coffee Break

Session 4: Scientific Bases of PG – 2. Transporters and Targets

Chair: Marçal Pastor Anglada, University of Barcelona, ES

11.00-11.30 Heyo Kroemer

University of Greifswald, DE

Physiological and pharmacological role of transporters in the

cardiovascular system

11.30-12.00 Mikko Niemi

University of Helsinki, FI

Role of OATP-transporters in the disposition of drugs

12.00-12.30 Otto-Erich Brodde

University of Essen Medical School, DE

Pharmacogenetics of beta-1 and beta-2 adrenoceptors

12.30-12.45 Elise Andrews (short talk)

Newcastle University, UK

Effects of flucloxacillin on CYP3A4 and drug transporter function and

expression in cultured cells

13.00 Lunch

14.30-16.00 Poster Session 2 16.00-16.30 Coffee Break

16.30-18.00 Poster Session 2 (continues)

Plenary Lecture 3

Chair: Leif Bertillson, Karolinska University Hospital, Stockholm, SE

18.00-19.00 Munir Pirmohamed

The University of Liverpool, UK

Pharmacogenetics: present situation and perspectives on clinical

applications

19.00 Dinner

Round Table 2: Clinical Applications of PG: Present Situation & Perspectives

Chair: Munir Pirmohamed, University of Liverpool, UK

21.00-21.15 Laurent Becquemont

Unite de Recherche Clinique Paris-Sud Hôpital Bicêtre, FR

The need for clinical trials

21.15-21.30 Ann Daly

University of Newcastle, UK

Relationship between clinical phenotype and genotype: current

perspectives

21.30-21.45 Adrian Llerena

Universitad de Beira Interior, Covilhã, PT

CYP2D6 pheno and genotype in psychiatric patients

21.45-22.15 Plenary Discussion

Monday 18 June

Session 5: Clinical Applications of PG – 1

Chair: Munir Pirmohamed, University of Liverpool, UK

09.00-09.30 Pierre Laurent-Puig

INSERM U775, Paris, FR

Genetics and targeted therapies

09.30-10.00 Colin Ross

University of British Columbia, CA

Pharmacogenomics of severe adverse drug reactions in children

10.00-10.15 Melih Babaoglu (short talk)

Hacettepe University, Ankara, TR

Association of the cytochrome P450 1A2*1F polymorphism with clozapine

response in schizophrenic patients

10.15-10.45 Coffee Break

Session 6: Clinical Applications of PG – 2

Chair: Magnus Ingelman-Sunberg, Karolinska Institute, Stockholm, SE

10.45-11.15 Leif Bertillson

Karolinska University Hospital, Stockholm, SE

Pharmacogenetics of depression and its treatment

11.15-11.45 Adrian Llerena and Pedro Dorado

Extremadura University Hospital and Medical School, Badajoz, ES

Schizophrenia and PG of neuroleptic drugs

11.45-12.15 Jules A. Desmeules

Geneva University Hospital, CH

PG of antalgics

12.15-12.30 Eleni Aklillu (short talk)

Karolinska Institute, Stockholm, SE

A functional polymorphism in the monoamine oxidase A gene is associated with atypical features of patients with major depression and variation in

CSF monoamine metabolite concentrations

12.30-12.45 Ana Alfirevic (short talk)
The University of Liverpool, UK

TNF, LTA, HSPA1L and HLA-DR Gene Polymorphisms in HIV positive

patients with hypersensitivity to co-trimoxazole

13.00 Lunch

14.30-16.00 Poster Session 3 16.00-16.30 Coffee Break

16.30-18.00 Poster Session 3 (continues)

18.00-19.00 Free time

19.30 Get-together & Conference Dinner

Tuesday 19 June

Session 7: Clinical Applications of PG – 3

Chair: Ann Daly, University of Newcastle, UK

08.30-09.00 Marie-Anne Loriot

INSERM U775, Paris, FR

Pharmacogenetics and oral anticoagulants

09.00-09.30 Dany Anglicheau

INSERM U775, Paris, FR

Immunosuppression: current status and future challenges

09.30-10.00 Takahisa Furuta

Hamamatsu University, JP

Pharmacogenetic approaches in the treatment of peptic ulcer and GERD

10.00-10.30 Sophie Visvikis-Siest

INSERM U525, Nancy, FR

Genetic of cardiovascular diseases

10.30-11.00 Coffee Break

11.00-11.15 Anke-Hilse Maitland-Van Der Zee

Utrecht University, NL

Interactions between the Gly460Trp alpha-adducin gene variant and diuretics and the risk of myocardial infarction among treated hypertensive

patients (short talk)

11.15-11.30 Ron Van Schaik (short talk)

Erasmus MC, Rotterdam, NL

Genetic polymorphisms in UGT1A9 explain part of the inter-individual variability in mycophenolate mofetil (MMF) pharmacokinetics in tacrolimus

co-treated patients

Session 8: Beyond Chips & SNPs

Chair: Heyo Kroemer, University of Greifswald, DE

11.30-12.00 Uwe Voelker

Ernst-Moritz-Arndt-University Greifswald, DE *Proteomics analysis of drug responses*

12.00-12.30 Elaine Holmes

Imperial College London, UK

Metabolomics and systems biology

13.00 Lunch

14.30-16.00 Poster Session 4 16.00-16.30 Coffee Break

Plenary Session

Chairs: Philippe Beaune, INSERM U775, FR, Marçal Pastor Anglada, University of Barcelona, ES,

Carole Moquin-Pattey, European Science Foundation, Strasbourg, FR

16.30-17.30 Business Meeting – Part 1

Identification of the focus and topics of the next conference. Presentation of

the candidate chairs

Round Table 3: Implications of PG for Pharmaceutical Industry and Agencies

Chair: Laurent Becquemont, Unite de Recherche Clinique Paris-Sud Hôpital Bicêtre, FR

17.30-17.50 Eleni Zika

IPTS Institute for Prospective Technological Studies, Sevilla, ES

Socio-economic impact of pharmacogenetics

17.50-18.10 James Creeden

F. Hoffmann-La Roche Ltd, Basel, CH

Health Economics of Pharmacogenetics and Pharmacogenomics

18.10-18.45 Plenary Discussion

18.45-19.00 Ballot vote to elect next chair

19.00 Dinner

Conclusions

Chairs: Philippe Beaune, INSERM U775, FR, Marçal Pastor Anglada, University of Barcelona, ES, Carole Moquin-Pattey, European Science Foundation, Strasbourg, FR

20.30-21.00 Philippe Beaune

INSERM U775, FR

21.00-22.00 Business Meeting – Part 2

Results of the elections, selection of the organising committee, suggestions

for the next conference

Wednesday 20 June

08.30-09.30 Breakfast & Departure

Abstracts, Posters & Short Oral Presentations

There will be no short talks other than those listed in the programme. All abstracts are accepted as posters. Posters will be displayed for the whole duration of the conference.